Published in Mol Immunol on March 01, 2002
Immunosenescence of ageing. J Pathol (2007) 3.32
Age-associated decline in T cell repertoire diversity leads to holes in the repertoire and impaired immunity to influenza virus. J Exp Med (2008) 3.15
Obesity increases the production of proinflammatory mediators from adipose tissue T cells and compromises TCR repertoire diversity: implications for systemic inflammation and insulin resistance. J Immunol (2010) 2.66
Immunosenescence: emerging challenges for an ageing population. Immunology (2007) 2.32
Thymic output in aged mice. Proc Natl Acad Sci U S A (2006) 2.24
Thymic involution and immune reconstitution. Trends Immunol (2009) 1.91
Sparse production but preferential incorporation of recently produced naive T cells in the human peripheral pool. Proc Natl Acad Sci U S A (2008) 1.62
Obesity accelerates thymic aging. Blood (2009) 1.59
Cytokines, leptin, and stress-induced thymic atrophy. J Leukoc Biol (2008) 1.47
Prolongevity hormone FGF21 protects against immune senescence by delaying age-related thymic involution. Proc Natl Acad Sci U S A (2016) 1.41
Control of central and peripheral tolerance by Aire. Immunol Rev (2011) 1.37
Age-associated increase in lifespan of naive CD4 T cells contributes to T-cell homeostasis but facilitates development of functional defects. Proc Natl Acad Sci U S A (2009) 1.34
Inhibition of thymic adipogenesis by caloric restriction is coupled with reduction in age-related thymic involution. J Immunol (2009) 1.28
Thymic progenitor homing and lymphocyte homeostasis are linked via S1P-controlled expression of thymic P-selectin/CCL25. J Exp Med (2009) 1.25
Leptin selectively augments thymopoiesis in leptin deficiency and lipopolysaccharide-induced thymic atrophy. J Immunol (2006) 1.25
Regeneration of the aged thymus by a single transcription factor. Development (2014) 1.23
Aging and immune function: molecular mechanisms to interventions. Antioxid Redox Signal (2011) 1.18
Resistance to age-dependent thymic atrophy in long-lived mice that are deficient in pregnancy-associated plasma protein A. Proc Natl Acad Sci U S A (2009) 1.15
The Nlrp3 inflammasome promotes age-related thymic demise and immunosenescence. Cell Rep (2012) 1.14
Immune senescence: relative contributions of age and cytomegalovirus infection. PLoS Pathog (2012) 1.13
Immunity, ageing and cancer. Immun Ageing (2008) 1.13
An IL-7-dependent rebound in thymic T cell output contributes to the bone loss induced by estrogen deficiency. Proc Natl Acad Sci U S A (2005) 1.13
Acute endotoxin-induced thymic atrophy is characterized by intrathymic inflammatory and wound healing responses. PLoS One (2011) 1.10
Factors that may impact on immunosenescence: an appraisal. Immun Ageing (2010) 1.09
Aged-related shifts in T cell homeostasis lead to intrinsic T cell defects. Semin Immunol (2012) 1.01
Bim dictates naive CD4 T cell lifespan and the development of age-associated functional defects. J Immunol (2010) 0.98
Thymic function is maintained during Salmonella-induced atrophy and recovery. J Immunol (2012) 0.98
IL-15 Fosters Age-Driven Regulatory T Cell Accrual in the Face of Declining IL-2 Levels. Front Immunol (2013) 0.96
Thymus Size and Age-related Thymic Involution: Early Programming, Sexual Dimorphism, Progenitors and Stroma. Aging Dis (2012) 0.93
Maintenance of naïve CD8 T cells in nonagenarians by leptin, IGFBP3 and T3. Mech Ageing Dev (2009) 0.92
Immune dysregulation after cardiothoracic surgery and incidental thymectomy: maintenance of regulatory T cells despite impaired thymopoiesis. Clin Dev Immunol (2011) 0.92
Thymic rejuvenation and the induction of tolerance by adult thymic grafts. Proc Natl Acad Sci U S A (2006) 0.91
Leptin receptor is expressed in thymus medulla and leptin protects against thymic remodeling during endotoxemia-induced thymus involution. J Endocrinol (2009) 0.91
Lifespan-extending caloric restriction or mTOR inhibition impair adaptive immunity of old mice by distinct mechanisms. Aging Cell (2014) 0.89
Thymopoiesis in elderly human is associated with systemic inflammatory status. Age (Dordr) (2009) 0.88
Thiazolidinedione treatment and constitutive-PPARgamma activation induces ectopic adipogenesis and promotes age-related thymic involution. Aging Cell (2010) 0.87
Thymic rejuvenation and aging. Curr Opin Immunol (2013) 0.86
Strategies for reconstituting and boosting T cell-based immunity following haematopoietic stem cell transplantation: pre-clinical and clinical approaches. Semin Immunopathol (2008) 0.86
Thymus-derived glucocorticoids mediate androgen effects on thymocyte homeostasis. FASEB J (2010) 0.85
Molecular measurement of T cell receptor excision circles. Methods Mol Biol (2013) 0.84
Inverse associations between obesity indicators and thymic T-cell production levels in aging atomic-bomb survivors. PLoS One (2014) 0.83
Reversal of age-related thymic involution by an LHRH agonist in miniature swine. Transpl Immunol (2010) 0.83
T cell ageing: effects of age on development, survival & function. Indian J Med Res (2013) 0.82
Adult thymus transplantation with allogeneic intra-bone marrow-bone marrow transplantation from same donor induces high thymopoiesis, mild graft-versus-host reaction and strong graft-versus-tumour effects. Immunology (2008) 0.81
Young, proliferative thymic epithelial cells engraft and function in aging thymuses. J Immunol (2015) 0.81
Regeneration of dendritic cells in aged mice. Cell Mol Immunol (2010) 0.81
Utilizing IL-12, IL-15 and IL-7 as Mucosal Vaccine Adjuvants. Lett Drug Des Discov (2006) 0.80
Greater than the sum of their parts: combination strategies for immune regeneration following allogeneic hematopoietic stem cell transplantation. Best Pract Res Clin Haematol (2011) 0.80
MCL1 increases primitive thymocyte viability in female mice and promotes thymic expansion into adulthood. Int Immunol (2011) 0.80
The aging immune system and its relationship with cancer. Aging health (2011) 0.79
Impact of ageing on the response and repertoire of influenza virus-specific CD4 T cells. Immun Ageing (2014) 0.79
Sex steroid ablation: an immunoregenerative strategy for immunocompromised patients. Bone Marrow Transplant (2015) 0.78
Quantification of baboon thymopoiesis in porcine thymokidney xenografts by the signal-joining T-cell receptor excision circle assay. Transplantation (2011) 0.78
IL-6 and ICOS Antagonize Bim and Promote Regulatory T Cell Accrual with Age. J Immunol (2015) 0.78
Increase in double-stranded DNA break-related foci in early-stage thymocytes of aged mice. Exp Gerontol (2009) 0.77
Longterm maintenance of human naive T cells through in situ homeostasis in lymphoid tissue sites. Sci Immunol (2016) 0.77
Temporal fate mapping reveals age-linked heterogeneity in naive T lymphocytes in mice. Proc Natl Acad Sci U S A (2015) 0.77
Signal joint T-cell receptor excision circle assay in miniature swine. Transplantation (2011) 0.76
The expansion of thymopoiesis in neonatal mice is dependent on expression of high mobility group a 2 protein (Hmga2). PLoS One (2015) 0.76
A quantitative study of the mechanisms behind thymic atrophy in Gαi2-deficient mice during colitis development. PLoS One (2012) 0.76
Elevated levels of interferon-γ production by memory T cells do not promote transplant tolerance resistance in aged recipients. PLoS One (2013) 0.75
Nab2 maintains thymus cellularity with aging and stress. Mol Immunol (2017) 0.75
Effects of recombinant human granulocyte colony-stimulating factor on central and peripheral T lymphocyte reconstitution after sublethal irradiation in mice. J Radiat Res (2012) 0.75
Long-term in vivo imaging of multiple organs at the single cell level. PLoS One (2013) 0.75
The rejuvenating effects of leuprolide acetate on the aged baboon's thymus. Transpl Immunol (2014) 0.75
Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A (2008) 16.54
A whole-genome association study of major determinants for host control of HIV-1. Science (2007) 15.19
Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science (2011) 7.92
Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing. J Virol (2008) 7.54
Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature (2011) 7.20
Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J Exp Med (2009) 7.01
The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. J Exp Med (2009) 6.22
The immune response during acute HIV-1 infection: clues for vaccine development. Nat Rev Immunol (2009) 5.99
Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature (2012) 5.44
Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature (2013) 5.35
Acute HIV-1 Infection. N Engl J Med (2011) 4.84
Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. Immunity (2013) 4.82
Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1. J Exp Med (2009) 4.79
Medicine. The need for a global HIV vaccine enterprise. Science (2003) 4.70
Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. J Virol (2011) 4.06
The characterization of twenty sequenced human genomes. PLoS Genet (2010) 3.72
High Multiplicity Infection by HIV-1 in Men Who Have Sex with Men. PLoS Pathog (2010) 3.68
Common genetic variation and the control of HIV-1 in humans. PLoS Genet (2009) 3.68
Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutinin. Proc Natl Acad Sci U S A (2011) 3.51
Antibody specificities associated with neutralization breadth in plasma from human immunodeficiency virus type 1 subtype C-infected blood donors. J Virol (2009) 3.36
HIV-1 neutralizing antibodies: understanding nature's pathways. Immunol Rev (2013) 3.30
A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses. Virology (2006) 3.26
Induction of immunity to human immunodeficiency virus type-1 by vaccination. Immunity (2010) 3.25
Role of HIV membrane in neutralization by two broadly neutralizing antibodies. Proc Natl Acad Sci U S A (2009) 3.19
Transmission of single HIV-1 genomes and dynamics of early immune escape revealed by ultra-deep sequencing. PLoS One (2010) 3.02
Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 group m consensus envelope glycoprotein. J Virol (2005) 2.89
Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials. J Infect Dis (2012) 2.89
Phenotypic properties of transmitted founder HIV-1. Proc Natl Acad Sci U S A (2013) 2.75
High-throughput isolation of immunoglobulin genes from single human B cells and expression as monoclonal antibodies. J Virol Methods (2009) 2.75
Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family. J Virol (2012) 2.74
Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG. Proc Natl Acad Sci U S A (2013) 2.69
Wide variation in the multiplicity of HIV-1 infection among injection drug users. J Virol (2010) 2.67
Generation of transmitted/founder HIV-1 infectious molecular clones and characterization of their replication capacity in CD4 T lymphocytes and monocyte-derived macrophages. J Virol (2011) 2.55
Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers. AIDS (2009) 2.53
Mosaic vaccines elicit CD8+ T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys. Nat Med (2010) 2.53
Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination. Sci Transl Med (2014) 2.47
Structural basis for diverse N-glycan recognition by HIV-1-neutralizing V1-V2-directed antibody PG16. Nat Struct Mol Biol (2013) 2.42
Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals. J Virol (2011) 2.42
Low-dose mucosal simian immunodeficiency virus infection restricts early replication kinetics and transmitted virus variants in rhesus monkeys. J Virol (2010) 2.39
Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01. J Virol (2011) 2.34
In vivo gp41 antibodies targeting the 2F5 monoclonal antibody epitope mediate human immunodeficiency virus type 1 neutralization breadth. J Virol (2009) 2.29
T-cell vaccine strategies for human immunodeficiency virus, the virus with a thousand faces. J Virol (2009) 2.17
Multidonor analysis reveals structural elements, genetic determinants, and maturation pathway for HIV-1 neutralization by VRC01-class antibodies. Immunity (2013) 2.17
HIV evolution in early infection: selection pressures, patterns of insertion and deletion, and the impact of APOBEC. PLoS Pathog (2009) 2.15
High-throughput quantitative analysis of HIV-1 and SIV-specific ADCC-mediating antibody responses. Cytometry A (2011) 2.14
Polyclonal B cell differentiation and loss of gastrointestinal tract germinal centers in the earliest stages of HIV-1 infection. PLoS Med (2009) 2.11
A critical role for CD8 T cells in a nonhuman primate model of tuberculosis. PLoS Pathog (2009) 2.09
H3N2 influenza infection elicits more cross-reactive and less clonally expanded anti-hemagglutinin antibodies than influenza vaccination. PLoS One (2011) 2.02
Isolation of a human anti-HIV gp41 membrane proximal region neutralizing antibody by antigen-specific single B cell sorting. PLoS One (2011) 1.99
Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutated. J Exp Med (2011) 1.97
The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120. AIDS Res Hum Retroviruses (2012) 1.94
Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial. PLoS One (2013) 1.94
Interaction with cellular CD4 exposes HIV-1 envelope epitopes targeted by antibody-dependent cell-mediated cytotoxicity. J Virol (2013) 1.93
Autoreactivity in an HIV-1 broadly reactive neutralizing antibody variable region heavy chain induces immunologic tolerance. Proc Natl Acad Sci U S A (2009) 1.93
Transmitted/founder and chronic subtype C HIV-1 use CD4 and CCR5 receptors with equal efficiency and are not inhibited by blocking the integrin α4β7. PLoS Pathog (2012) 1.88
Two distinct broadly neutralizing antibody specificities of different clonal lineages in a single HIV-1-infected donor: implications for vaccine design. J Virol (2012) 1.86
The transmembrane hyaluronate receptor (CD44): multiple functions, multiple forms. Cancer Cells (1991) 1.85
Phenotypic and functional profile of HIV-inhibitory CD8 T cells elicited by natural infection and heterologous prime/boost vaccination. J Virol (2010) 1.81
A centralized gene-based HIV-1 vaccine elicits broad cross-clade cellular immune responses in rhesus monkeys. Proc Natl Acad Sci U S A (2008) 1.80
Glycosylation site-specific analysis of HIV envelope proteins (JR-FL and CON-S) reveals major differences in glycosylation site occupancy, glycoform profiles, and antigenic epitopes' accessibility. J Proteome Res (2008) 1.73
CCL3L1 and HIV/AIDS susceptibility. Nat Med (2009) 1.73
Envelope deglycosylation enhances antigenicity of HIV-1 gp41 epitopes for both broad neutralizing antibodies and their unmutated ancestor antibodies. PLoS Pathog (2011) 1.70
Preconfiguration of the antigen-binding site during affinity maturation of a broadly neutralizing influenza virus antibody. Proc Natl Acad Sci U S A (2012) 1.70
Induction of plasma (TRAIL), TNFR-2, Fas ligand, and plasma microparticles after human immunodeficiency virus type 1 (HIV-1) transmission: implications for HIV-1 vaccine design. J Virol (2008) 1.69
Identification of autoantigens recognized by the 2F5 and 4E10 broadly neutralizing HIV-1 antibodies. J Exp Med (2013) 1.68
HIV-1-specific antibody responses during acute and chronic HIV-1 infection. Curr Opin HIV AIDS (2009) 1.67
Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDSVAX HIV-1 vaccine efficacy trial. PLoS One (2013) 1.65
Cross-subtype T-cell immune responses induced by a human immunodeficiency virus type 1 group m consensus env immunogen. J Virol (2006) 1.63
HIV-1 infection-induced apoptotic microparticles inhibit human DCs via CD44. J Clin Invest (2012) 1.63
Ancestral and consensus envelope immunogens for HIV-1 subtype C. Virology (2006) 1.62
Glycosylation site-specific analysis of clade C HIV-1 envelope proteins. J Proteome Res (2009) 1.61
Early low-titer neutralizing antibodies impede HIV-1 replication and select for virus escape. PLoS Pathog (2012) 1.61
Molecular characterization of the mouse involuted thymus: aberrations in expression of transcription regulators in thymocyte and epithelial compartments. Int Immunol (2002) 1.58
Characterization of glycosylation profiles of HIV-1 transmitted/founder envelopes by mass spectrometry. J Virol (2011) 1.58
Recurrent signature patterns in HIV-1 B clade envelope glycoproteins associated with either early or chronic infections. PLoS Pathog (2011) 1.57
Phenotypic and immunologic comparison of clade B transmitted/founder and chronic HIV-1 envelope glycoproteins. J Virol (2011) 1.55
A short segment of the HIV-1 gp120 V1/V2 region is a major determinant of resistance to V1/V2 neutralizing antibodies. J Virol (2012) 1.54
The development of CD4 binding site antibodies during HIV-1 infection. J Virol (2012) 1.53
Immune distribution and localization of phosphoantigen-specific Vgamma2Vdelta2 T cells in lymphoid and nonlymphoid tissues in Mycobacterium tuberculosis infection. Infect Immun (2007) 1.52
Mining the antibodyome for HIV-1-neutralizing antibodies with next-generation sequencing and phylogenetic pairing of heavy/light chains. Proc Natl Acad Sci U S A (2013) 1.51
Role of immune mechanisms in induction of HIV-1 broadly neutralizing antibodies. Curr Opin Immunol (2011) 1.51
Expanded breadth of the T-cell response to mosaic human immunodeficiency virus type 1 envelope DNA vaccination. J Virol (2008) 1.51
Antigenicity and immunogenicity of HIV-1 consensus subtype B envelope glycoproteins. Virology (2006) 1.51
Genetic signatures in the envelope glycoproteins of HIV-1 that associate with broadly neutralizing antibodies. PLoS Comput Biol (2010) 1.51
Copy number variation of KIR genes influences HIV-1 control. PLoS Biol (2011) 1.44
Comparison of HIV Type 1 ADA gp120 monomers versus gp140 trimers as immunogens for the induction of neutralizing antibodies. AIDS Res Hum Retroviruses (2005) 1.44
Relationship between functional profile of HIV-1 specific CD8 T cells and epitope variability with the selection of escape mutants in acute HIV-1 infection. PLoS Pathog (2011) 1.42
HIV-1 gp120 vaccine induces affinity maturation in both new and persistent antibody clonal lineages. J Virol (2012) 1.39
HIV-1 envelope induces memory B cell responses that correlate with plasma antibody levels after envelope gp120 protein vaccination or HIV-1 infection. J Immunol (2009) 1.39
Induction of HIV-1 broad neutralizing antibodies in 2F5 knock-in mice: selection against membrane proximal external region-associated autoreactivity limits T-dependent responses. J Immunol (2013) 1.39
Efficacy and safety of live attenuated persistent and rapidly cleared Mycobacterium tuberculosis vaccine candidates in non-human primates. Vaccine (2009) 1.38
High throughput functional analysis of HIV-1 env genes without cloning. J Virol Methods (2007) 1.35
In vitro and in vivo characterization of anthrax anti-protective antigen and anti-lethal factor monoclonal antibodies after passive transfer in a mouse lethal toxin challenge model to define correlates of immunity. Infect Immun (2007) 1.33
Common human genetic variants and HIV-1 susceptibility: a genome-wide survey in a homogeneous African population. AIDS (2011) 1.33
Utilization of immunoglobulin G Fc receptors by human immunodeficiency virus type 1: a specific role for antibodies against the membrane-proximal external region of gp41. J Virol (2009) 1.32